NEO-201 is under clinical development by Precision Biologics and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NEO-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NEO-201 overview

NEO-201 (h16C3) is under development for the treatment of non small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, uterine cancer and endometrial cancer. It is a humanized IgG1 monoclonal antibody that acts by targeting cells expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM-5) and carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM-6). It was also under development for the treatment of esophageal cancer, gastric cancer, laryngeal cancer and colorectal cancer, pancreatic cancer, adenocarcinoma of the lung, squamous cell lung cancer, breast cancer, mucinous and signet cell ovarian cancer.

Precision Biologics overview

Precision Biologics (PBI), a subsidiary of NantWorks LLC, is a clinical-stage biotechnology company. The company offers cancer vaccines, antigens and antibodies, pipelines, diagnostics, therapeutics, clinical trials, tumor-specific antigens, companion diagnostic programs, and diagnostic biomarker for pancreatic and colorectal cancers. It provides services such as development of pharmaceutical and diagnostic products for the early detection and treatment of cancer and developing innovative diagnostics and therapeutics that target tumors with precision. PBI also provides therapeutic drug candidate for pancreatic and colorectal cancers, therapeutic drug, tumor-specific antigen, pre-clinical tests, experimental therapy, and other diagnostic programs. The company offers services such as discovery, development and commercialization of novel cancer therapeutics and diagnostics. It has operations in Dallas, Rockville, and New York. PBI is headquartered in Rockville, Maryland, the US.

For a complete picture of NEO-201’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.